Hormone Therapy and Heart Risk: Why the 2002 Warning Doesn't Apply the Way Most Women Were Told

If you've avoided hormone therapy, or had a clinician steer you away from it, there's a good chance a single 2002 study is the reason — even if no one mentioned it by name. It's worth understanding what that study actually showed, because the picture has changed substantially since then, most recently with a large reanalysis published in November 2025.

What the original study actually found

The Women's Health Initiative was a large, well-designed federal trial, and the alarm it raised in 2002 was real: women randomized to estrogen plus progestin had a statistically significant increase in breast cancer, cardiovascular events, and stroke compared to placebo, enough that the combined-hormone arm of the trial was stopped early.¹ That finding reshaped how an entire generation of clinicians — mine included, by training — approached hormone therapy, and prescribing dropped sharply within a few years of publication.

What got lost in the headlines was who was actually in the trial. The average participant was just past 63, and many had gone through menopause a decade or more before enrolling.² Almost no one asked whether starting hormone therapy at 52, right at the onset of symptoms, carries the same risk profile as starting it for the first time at 72. The trial wasn't designed to answer that question, and for two decades, most of the guidance built on it didn't distinguish between those two women.

The timing hypothesis

The theory that emerged from later analysis of the same WHI data is often called the timing hypothesis: estrogen appears to behave differently in blood vessels that are still relatively healthy than in vessels that have already spent years adapting to low estrogen. Started close to menopause, it may support vascular function. Started a decade or more later, in someone whose arteries have already changed, the same hormone may behave differently and less favorably.³

This isn't a new or fringe idea — it's been part of mainstream guidance for over a decade, and a comprehensive 2024 review in JAMA explicitly supports initiating hormone therapy before age 60 or within 10 years of menopause for symptomatic women without contraindications.⁴ What's been missing is precise, age-stratified data from the trial that started the whole conversation.

What the November 2025 reanalysis adds

That's what changed recently. Researchers went back to WHI data on more than 27,000 postmenopausal women and specifically asked how cardiovascular outcomes differed by age and by whether a woman had moderate-to-severe hot flashes at enrollment — the group most likely to actually be offered hormone therapy in practice.⁵

For women in their 50s with vasomotor symptoms, the analysis found no meaningful increase in cardiovascular risk from hormone therapy. Risk rose with age, and was clearly elevated in women starting therapy in their 70s. That's the age-stratified confirmation the timing hypothesis had been arguing for since the mid-2000s, now shown directly in the trial that originally raised the alarm — not a smaller or lower-quality study contradicting it.

Where I'd still be careful

None of this makes hormone therapy risk-free, and I don't want to overstate what a reanalysis of one trial, however large, can settle on its own. A few things are still true regardless of age:

• The original breast cancer signal in the combined estrogen-progestin arm was real, and personal or family history still matters when weighing hormone therapy.
• Formulation and route of delivery appear to matter — transdermal estrogen and oral estrogen don't carry identical risk profiles, and that's an active area of ongoing research rather than a settled question.
• This is population-level data. It tells you what happened, on average, to thousands of women in a specific age range — not what will happen to you specifically, which depends on your own history.

Where this leaves the conversation

For a lot of women in their late 40s and 50s dealing with real symptoms — sleep disruption, hot flashes, mood changes — the data now says the cardiovascular caution that shaped care for two decades doesn't apply to them the way it was applied. That's worth knowing before deciding hormone therapy isn't an option, and it's a very different conversation than the one most people had with a clinician ten or fifteen years ago.

If hormone-related symptoms are part of what you're dealing with, I've also written about the DUTCH test, which is sometimes useful for mapping the pattern of what's happening rather than a single point-in-time hormone level. And if you're trying to figure out whether what you're feeling is perimenopause, thyroid, or something else entirely, that's exactly the kind of question worth bringing to a visit.

Sources

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
2. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
3. Clarkson TB, Meléndez G, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20(3):342–353.
4. Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748–1760.
5. Rossouw JE, Aragaki AK, Manson JE, et al. Menopausal hormone therapy and cardiovascular diseases in women with vasomotor symptoms: a secondary analysis of the Women's Health Initiative randomized clinical trials. JAMA Intern Med. 2025;185(11):1330–1339.